BR0316203A - Uso de um agente antialérgico e um esteróide para tratar rinite alérgica - Google Patents

Uso de um agente antialérgico e um esteróide para tratar rinite alérgica

Info

Publication number
BR0316203A
BR0316203A BR0316203-6A BR0316203A BR0316203A BR 0316203 A BR0316203 A BR 0316203A BR 0316203 A BR0316203 A BR 0316203A BR 0316203 A BR0316203 A BR 0316203A
Authority
BR
Brazil
Prior art keywords
steroid
allergic rhinitis
treat allergic
antiallergic agent
antiallergic
Prior art date
Application number
BR0316203-6A
Other languages
English (en)
Inventor
Gerald D Cagle
G Michael Wall
John M Yanni
Rajni Jani
Haresh G Bhagat
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0316203A publication Critical patent/BR0316203A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"USO DE UM AGENTE ANTIALéRGICO E UM ESTERóIDE PARA TRATAR RINITE ALéRGICA". A presente invenção refere-se a composições e métodos para o tratamento de rinite com certas combinações de agentes antialérgicos e esteróides.
BR0316203-6A 2002-11-12 2003-11-12 Uso de um agente antialérgico e um esteróide para tratar rinite alérgica BR0316203A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42549402P 2002-11-12 2002-11-12
PCT/US2003/036054 WO2004043470A1 (en) 2002-11-12 2003-11-12 The use of an anti-allergy agent and a steroid to treat allergic rhinitis

Publications (1)

Publication Number Publication Date
BR0316203A true BR0316203A (pt) 2005-10-04

Family

ID=32312998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316203-6A BR0316203A (pt) 2002-11-12 2003-11-12 Uso de um agente antialérgico e um esteróide para tratar rinite alérgica

Country Status (12)

Country Link
US (1) US20040097474A1 (pt)
EP (1) EP1560586A1 (pt)
JP (1) JP2006508138A (pt)
KR (1) KR20050074577A (pt)
CN (1) CN1297275C (pt)
AU (1) AU2003291497B2 (pt)
BR (1) BR0316203A (pt)
CA (1) CA2504200A1 (pt)
MX (1) MXPA05005044A (pt)
PL (1) PL376970A1 (pt)
WO (1) WO2004043470A1 (pt)
ZA (1) ZA200503243B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055152A1 (en) * 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
DK1545548T3 (da) * 2002-08-30 2010-09-27 Nycomed Gmbh Anvendelsen af kombinationen af ciclesonid og antihistaminer til behandingen af allergisk rhinitis
US20050222049A1 (en) * 2004-03-31 2005-10-06 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20090317477A1 (en) * 2004-03-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20050227927A1 (en) * 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
CA2580659C (en) * 2004-09-15 2013-02-26 Ivx Animal Health, Inc. Corticosteroid having low systemic absorption
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
ZA200704139B (en) * 2004-11-24 2008-10-29 Alcon Inc Method of delivering nasal spray
MX2007006233A (es) * 2004-11-24 2007-11-23 Medpointe Healthcare Inc Composiciones que comprenden azelastina y metodos de uso de la misma.
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) * 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
PT2114367E (pt) * 2007-02-07 2016-02-01 Novartis Ag Formulações de olopatadina para administração nasal tópica
US20100227917A1 (en) * 2007-09-06 2010-09-09 Masashi Nakakura EYE DROP CONTAINING DIBENZ[b,e]OXEPIN DERIVATIVE
CN102065850A (zh) * 2008-07-07 2011-05-18 博磊科技股份有限公司 带静电荷的鼻应用多用途产品和方法
JP2012504974A (ja) * 2008-08-26 2012-03-01 トルテック コーポレーション 静電的に帯電したフィルターマスク製品及びフィルター効率を増大させるための方法
JP2012509250A (ja) * 2008-08-28 2012-04-19 トルテック コーポレーション 抗ヒスタミン及び抗ヒスタミン様経鼻適用製品及び方法
CN102018680B (zh) * 2009-09-18 2012-02-29 华北制药股份有限公司 一种富马酸依美斯汀缓释片及其制备方法
WO2011141929A2 (en) * 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
US9937189B2 (en) * 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
LT3043773T (lt) * 2013-09-13 2021-10-11 Glenmark Specialty S.A. Stabilios fiksuotos dozės farmacinė kompozicija, kurioje yra mometazono ir olopatadino, skirta naudoti į nosį
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN105792828A (zh) * 2013-10-04 2016-07-20 格兰马克药品有限公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
MX2020008741A (es) * 2018-02-23 2020-09-28 Glenmark Specialty Sa Tratamiento de la rinitis alergica en sujetos pediatricos con una combinacion de mometasona y olopatadina.
CN115279364A (zh) * 2019-12-06 2022-11-01 东兴药品工业株式会社 包含甾体化合物和奥洛他定的药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3662944B2 (ja) * 1993-08-24 2005-06-22 協和醗酵工業株式会社 点鼻剤
JP3696265B2 (ja) * 1994-02-04 2005-09-14 日本オルガノン株式会社 点鼻液剤
WO1997001337A1 (en) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
AU3153797A (en) * 1996-06-04 1998-01-05 Procter & Gamble Company, The A nasal spray containing an intranasal steroid and an antihistamine
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
AR025964A1 (es) * 1999-10-08 2002-12-26 Schering Corp Tratamiento nasal topico
MXPA02005007A (es) * 1999-11-18 2004-08-12 Alcon Inc Uso de un antagonista h1 y un esteroide inocuo para tratar condiciones oculares.
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
JP2005511724A (ja) * 2001-12-05 2005-04-28 アルコン，インコーポレイテッド 鼻炎を処置するためのｈ１アンタゴニストおよび安全なステロイドの使用

Also Published As

Publication number Publication date
ZA200503243B (en) 2006-06-28
MXPA05005044A (es) 2005-07-01
WO2004043470A1 (en) 2004-05-27
JP2006508138A (ja) 2006-03-09
AU2003291497A1 (en) 2004-06-03
AU2003291497B2 (en) 2007-12-20
EP1560586A1 (en) 2005-08-10
CN1297275C (zh) 2007-01-31
US20040097474A1 (en) 2004-05-20
KR20050074577A (ko) 2005-07-18
CN1711092A (zh) 2005-12-21
CA2504200A1 (en) 2004-05-27
PL376970A1 (pl) 2006-01-23

Similar Documents

Publication Publication Date Title
BR0316203A (pt) Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
CY1105607T1 (el) Η χρηση ενος η1 ανταγωνιστη και ριμεξαολης ως ενα ασφαλες στεροειδες για την θεραπεια ρινιτιδας
DE60233212D1 (de) Immunstimulierende beschichtung für chirurgische vorrichtungen
BR0307772A (pt) Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência
EE05417B1 (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias
PT1039912E (pt) Agentes angiostaticos e composicoes para tratar glaucoma glc1a
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
ATE468889T1 (de) Kosmetische zusammensetzung zur behandlung von alternder und/oder gestresster haut
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
CL2004000026A1 (es) Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BR0312092A (pt) Uso de derivados de tio-oxindol no tratamento de distúrbios da pele
BR0011225A (pt) Agente para tratar de olhos secos, seu método e uso
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
BR0210101A (pt) Combinações antineoplásticas
AR054435A1 (es) Agente para profilaxis o terapia contra la depresion o desorden de ansiedad
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.